# US 8,278,098 B2 · Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,098 B2
- Document ID: US8278098B2
- Status: Granted
- Kind: B2
- Application number: 13/016,728
- Filed: 2011-01-28
- Published: 2011-08-25
- Granted: 2012-10-02
- Earliest claimed: 2000-02-25
- Assignees: Vegenics Pty Limited
- Inventors: Kari Alitalo; Markku M. Jeltsch
- Web page: https://patentgrep.com/patent/US8278098B2

## CPC

- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- C12N 5/069: {Vascular Endothelial cells}
- C12N 5/0692: {Stem cells; Progenitor cells; Precursor cells}
- C07K 2319/00: Fusion polypeptide
- C12N 2501/165: Vascular endothelial growth factor [VEGF]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth factors.

## Claims

### Claim 1

A method of modulating the growth of mammalian endothelial cells or mammalian endothelial precursor cells, comprising contacting the cells with a polypeptide comprising an amino acid sequence that is at least 95% identical to a chimeric vascular endothelial growth factor (VEGF) amino acid sequence selected from the group consisting of SEQ ID NO: 241 (construct 11-3) or SEQ ID NO: 209 (construct 13-1),
wherein the polypeptide binds to human VEGFR-1 and human VEGFR-2, and
wherein the polypeptide further includes one or more amino acid sequences selected from the group consisting of a prepro-VEGF-C signal peptide, a prepro-VEGF-C amino-terminal propeptide, and a prepro-VEGF-C carboxy-terminal pro-peptide.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the contacting comprises administering a composition comprising said polypeptide and a pharmaceutically acceptable carrier to a mammalian subject.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the mammalian subject is a human.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the polypeptide comprises a prepro-VEGF-C carboxy terminal propeptide.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the polypeptide is purified.

### Claim 6

A method of modulating the growth of mammalian hematopoietic progenitor cells, comprising the step of contacting the cells with a polypeptide in an amount effective to modulate the growth of the cells, wherein the polypeptide comprising an amino acid sequence of the formula:
XN-V/PHD-XC,
wherein XN comprises amino acids 1-111 of SEQ ID NO: 22 or a fragment thereof;
wherein V/PHD comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 241 (construct 11-3) or SEQ ID NO: 209 (construct 13-1);
wherein XC comprises amino acids 217-419 of SEQ ID NO: 22 or a fragment thereof;
wherein XN and XC are each identical to an amino acid sequence in a naturally occurring human VEGF-C precursor protein; and
wherein the polypeptide binds human VEGFR-1 and human VEGFR-2.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the contacting comprises administering a composition comprising said polypeptide and a pharmaceutically acceptable carrier to a mammalian subject.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the mammalian subject is a human.

### Claim 9 (depends on 6)

The method according to claim 6, wherein the polypeptide is purified.

### Claim 10

A method of modulating the growth of mammalian endothelial cells or mammalian endothelial precursor cells, comprising contacting the cells with a polypeptide comprising an amino acid sequence of the formula:
XN-V/PHD-XC,
wherein XN comprises amino acids 1-111 of SEQ ID NO: 22 or a fragment thereof;
wherein V/PHD comprises an amino acid sequence at least 95% identical to an amino acid sequence of the formula:
NH2-X1-X2-X3-X4-X5-X6-X7-X8-X9-COOH
wherein X1 is amino acids 3-11 of SEQ ID NO: 128; wherein X2 is SEQ ID NO: 129; wherein X3 is SEQ ID NO: 130; wherein X4 is SEQ ID NO: 131; wherein X5 is SEQ ID NO: 132; wherein X6 is SEQ ID NO: 142; wherein X7 is SEQ ID NO: 134; wherein X8 is SEQ ID NO: 135; and wherein X9 is SEQ ID NO: 136; or
wherein X1 is amino acids 3-11 of SEQ ID NO: 128; wherein X2 is SEQ ID NO: 129; wherein X3 is SEQ ID NO: 130; wherein X4 is SEQ ID NO: 131; wherein X5 is SEQ ID NO: 141; wherein X6 is SEQ ID NO: 133; wherein X7 is SEQ ID NO: 134; wherein X8 is SEQ ID NO: 135; and wherein X9 is SEQ ID NO: 136;
wherein XC comprises amino acids 217-419 of SEQ ID NO: 22 or a fragment thereof;
wherein XN and XC are each identical to an amino acid sequence in a naturally occurring human VEGF-C precursor protein; and
wherein the polypeptide binds to human VEGFR-1 and human VEGFR-2.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the contacting comprises administering a composition comprising said polypeptide and a pharmaceutically acceptable carrier to a mammalian subject.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the mammalian subject is a human.
